CivicaRx wants to change drug costs by working with pharma

Amy Baxter | | Health Exec | Policy & Regulations

CivicaRx, the not-for-profit entity created last year by a group of health systems and hospitals, is planning to achieve its goals of lowering drug prices and addressing shortages in hospitals by working directly with pharmaceutical companies and buying drugs, Bloomberg reported.

When the entity first came to fruition, its stated goal was to manufacture its own drugs after hospitals faced shortages for many common drugs. For now, it seems CivicaRx will serve as a marketplace entity, buying drugs from pharmaceutical companies and acting as a go-between for hospitals, according to Bloomberg.

“With that critical need, almost a national drug-shortage crisis, we had to discover what was the fastest way to get products into the market,” CivicaRx CEO Martin VanTrieste told Bloomberg.

See the full story below:

Nonprofit Trying to Upend Drug Costs Will Work With Pharma, Not Against It

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

More than 1,000 hospitals earn $700M opioid crisis judgment
VA planning 83,000 layoffs as part of restructuring
HIMSS survey report: Beware insider threats to cybersecurity involving AI
HHS spokesperson abruptly resigns, reportedly after clash with RFK
Hospital faces $3.5M settlement after sharing patient data with Facebook
Philips pulls endovascular devices from market after safety issues prompt Class I recall

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.